A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Weekly and Monthly Dosing Results in Patients with Hemophilia A or B
暂无分享,去创建一个
A. Akinc | D. Bevan | K. Pasi | T. Lissitchkov | M. Ragni | C. Hay | S. Rangarajan | B. Sørensen | Jihong Chen | S. Austin | R. Kazmi | B. Brand | P. Chowdary | T. Mant | P. Georgiev | M. D. Creagh